SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations

References

• EMA. New add-on treatment to insulin for treatment of certain patients with type 1 diabetes. Available from: https://www.ema.europa.eu/en/news/new-add-treatment-insulin-treatment-certain-patients-type-1-diabetes. Accessed October 25, 2023.
   Google Scholar
• EMA. First oral add-on treatment to insulin for the treatment of certain patients with type 1 diabetes. Available from: https://www.ema.europa.eu/en/documents/press-release/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes_. Accessed October 25, 2023.
   Google Scholar
• Dandona P, Mathieu C, Philip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;11(5):864–876. doi:10.1016/S2213-8587(17)30308-X
   Google Scholar
• Mathieu C, Dandona P, Gillard P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938–1946. doi:10.2337/dc18-0623
   PubMed Web of Science ®Google Scholar
• Garg SK, Henry RR, Banks P. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337–2348. doi:10.1056/NEJMoa1708337
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Update on US regulatory decision for Forxiga in type-1 diabetes. Available from: https://www.astrazeneca.com. Accessed July 15, 2019.
   Google Scholar
• NICE. NICE technology appraisal guidance TA597. Dapagliflozin with insulin for treating type 1 diabetes. Available from: https://www.nice.org.uk/guidance/ta597. Accessed August 28, 2019.
   Google Scholar
• AIFA. Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus. Available from: https://www.aifa.gov.it/documents/20142/1313724/2021.10.29_NII_FORXIGA-dapagliflozin_EN.pdf. Accessed October 25, 2023.
   Google Scholar
• EMA. Zynquista (sotagliflozin) An overview of Zynquista and why it is authorised in the EU; 2019. Available from: https://www.ema.europa.eu/en/documents/overview/zynquista-epar-medicine-overview_en.pdf. Accessed October 25, 2023.
   Google Scholar
• Sanofi. FDA issues Complete Response Letter for Zynquista (sotagliflozin). Available from: http://www.news.sanofi.us/2019-03-22-FDA-issues-Complete-Response-Letter-for-Zynquista-TM-sotagliflozin. Accessed October 25, 2023.
   Google Scholar
• EMA. Zynquista. Withdrawal of the marketing authorisation in the European Union. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-zynquista-withdrawal-marketing-authorisation-european-union_en.pdf. Accessed August 16, 2022.
   Google Scholar
• Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;12(41):2560–2569. doi:10.2337/dc18-1749
   Google Scholar
• Pasqua MR, Jafar A, Kobayati A, et al. Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in adults with suboptimally controlled type 1 diabetes: a randomized crossover controlled trial. Diabetes Care. 2023;1(46):165–172. doi:10.2337/dc22-0490
   Google Scholar
• Diabetes.co.uk, FDA rejects approval of empagliflozin for type 1 diabetes. Available from: https://www.diabetes.co.uk/news/2019/Nov/fda-rejects-approval-of-empagliflozin-for-type-1-diabetes.html. Accessed October 25, 2023.
   Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs. 2015;75(1):33–59. doi:10.1007/s40265-014-0337-y
   PubMed Web of Science ®Google Scholar
• A.j S. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015;54(7):691–708. doi:10.1007/s40262-015-0264-4
   PubMed Web of Science ®Google Scholar
• Dapaglifozin Compound summary PubChem. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dapagliflozin. Accessed October 25, 2023.
   Google Scholar
• Canaglifozin compound summary pubchem. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Canagliflozin. Accessed October 25, 2023.
   Google Scholar
• Empaglifozin Compound summary Pubchem. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Empagliflozin#:~:text=Empagliflozin%20is%20a%20C%2Dglycosyl,group%20at%20the%20anomeric%20centre. Accessed October 25, 2023.
   Google Scholar
• Alkabbani W, Gamble JM. Profile of Ipragliflozin, an oral SGLT-2 inhibitor for the treatment of type 2 diabetes: the evidence to date drug design. Dev Ther. 2021;5:3057–3069. doi:10.2147/DDDT.S281602
   Google Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306(2):194–204. doi:10.1152/ajprenal.00520.2013
   PubMed Web of Science ®Google Scholar
• Song P, Huang W, Onishi A, et al. Knockout of Na+-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltration. Am J Physiol Renal Physiol. 2019;1(317):207–217. doi:10.1152/ajprenal.00120.2019
   Google Scholar
• Huang F, Zhao Y, Wang Q, et al. Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1/TGFβ1 signaling. Front Endocrinol. 2019;10(441). doi:10.3389/fendo.2019.00441
   Google Scholar
• Cheng ST, Chen L, Li SY, et al. The Effects of Empagliflozin, an sglt2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes. PLoS One. 2016;11(1). doi:10.1371/journal.pone.0147391
   Web of Science ®Google Scholar
• Zhang B, Zhai M, Li B, et al. Honokiol ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by reducing oxidative stress and apoptosis through activating the SIRT1-Nrf2 signaling pathway. Oxid Med Cell Longev. 2018;2018. doi:10.1155/2018/3159801
   Web of Science ®Google Scholar
• Jiang K, Xu Y, Wang D, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022;13(5):336–359. doi:10.1007/s13238-020-00809-4
   PubMed Web of Science ®Google Scholar
• Terasaki M, Hiromura M, Mori Y. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One. 2015;10(11):e0143396. doi:10.1371/journal.pone.0143396
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang X, Wang Q, et al. Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front Endocrinol. 2022;13. doi:10.3389/fendo.2022.992937
   Web of Science ®Google Scholar
• Eid SA, O’Brien PD, Hinder LM, et al. Differential effects of empagliflozin on microvascular complications in murine models of type 1 and type 2 diabetes. Biology. 2020;9(11):347. doi:10.3390/biology9110347
   PubMed Web of Science ®Google Scholar
• Veelen A, Andriessen C, Op den Kamp Y. “Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial”. Metabolism. 2023;140:155396. PMID: 36592688. doi:10.1016/j.metabol.2022.155396
   PubMed Web of Science ®Google Scholar
• Clemmensen KKB, Blond MB, Amadid H, et al. No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: a post hoc analysis from the randomized controlled PRE-D trial. Diabetes Obes Metab. 2021;23(2):530–539. PMID: 33146457.
   PubMed Web of Science ®Google Scholar
• Mori Y, Duru OK, Et Al TKR. Sodium-glucose cotransporter 2 inhibitors and new-onset type 2 diabetes in adults with prediabetes: systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2022;108(1):221–231. PMID: 36217306. doi:10.1210/clinem/dgac591
   PubMedGoogle Scholar
• Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012;35(11):2198–2200. doi:10.2337/dc12-0508
   PubMed Web of Science ®Google Scholar
• Henry RR, Rosenstock J, s E, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412–419. doi:10.2337/dc13-2955
   PubMed Web of Science ®Google Scholar
• Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab. 2016;101(9):3506–3515. doi:10.1210/jc.2016-1451
   PubMed Web of Science ®Google Scholar
• Melmer A, Kempf P, Lungen L, et al. Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: a randomized, placebo-controlled, double blind, cross-over pilot study. Diabetes Obes Metab. 2018;20(11):2685–2689. doi:10.1111/dom.13439
   PubMed Web of Science ®Google Scholar
• Watada H, Shiramoto M, Ueda S, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes Obes Metab. 2019;21(4):876–882. doi:10.1111/dom.13593
   PubMed Web of Science ®Google Scholar
• Parkinson J, Weifeng T, Magnus A, et al. Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Diabetes Obes Metab. 2018;2018:1.
   Google Scholar
• Phillip M, Mathieu C, Lind M, et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and −2 studies. Diabetes Obes Metab. 2021;23(2):549–560. doi:10.1111/dom.14248
   PubMed Web of Science ®Google Scholar
• Biester T, Muller I, von Dem Berge T, et al. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: the DAPADream study. Diabetes Obes Metab. 2021;23(2):599–608. doi:10.1111/dom.14258
   PubMed Web of Science ®Google Scholar
• Araki E, Watada H, Uchigata Y, et al. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, Phase III clinical trial. Diabetes Obes Metab. 2020;22(4):540–548. doi:10.1111/dom.13922
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Hashimoto Y, Tanaka T, et al. multicenter, open-label, 2-arm, pilot trial for safe reduction of basal insulin dose combined with SGLT2 inhibitor in type 1 diabetes mellitus: study protocol for a RISING-STAR trial. Clin Med Insights Endocrinol Diabetes. 2021;14:117955142110405. doi:10.1177/11795514211040539
   Web of Science ®Google Scholar
• Urakami T, Yoshida K, Suzuki J. Efficacy of low-dose dapagliflozin in young people with type 1 diabetes. Intern Med. 2023;62(2):177–186. doi:10.2169/internalmedicine.9632-22
   PubMed Web of Science ®Google Scholar
• Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38(7):1181–1188. doi:10.2337/dc14-2806
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Freiman J, Brown PM. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92(2):158–169. doi:10.1038/clpt.2012.58
   PubMed Web of Science ®Google Scholar
• Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41(9):1970–1980. doi:10.2337/dc18-0343
   PubMed Web of Science ®Google Scholar
• Danne T, Cariou B, Buse JB, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41(9):1981–1990. doi:10.2337/dc18-0342
   PubMed Web of Science ®Google Scholar
• Danne T, Cariou B, Buse P, et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program. Diabetes Care. 2019;42(5):919–930. doi:10.2337/dc18-2149
   PubMed Web of Science ®Google Scholar
• Baker C, Wason S, Banks P, et al. ”Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: the inTandem4 trial. Diabetes Obes Metab. 2019;21(11):2440–2449. doi:10.1111/dom.13825
   PubMed Web of Science ®Google Scholar
• Henry RR, Thakkar P, Tang C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–2265. doi:10.2337/dc15-1730
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Peters AL, Slee A, et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care. 2017;40(2):171–180. doi:10.2337/dc16-1353
   PubMed Web of Science ®Google Scholar
• Kaku K, Isaka H, Toyoshima J, et al. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: a phase 2, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019;21(6):1445–1454. doi:10.1111/dom.13679
   PubMed Web of Science ®Google Scholar
• Kaku K, Isaka H, Sakatani T, et al. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial. Diabetes Obes Metab. 2019;21(10):2284–2293. doi:10.1111/dom.13807
   PubMed Web of Science ®Google Scholar
• Shimoda M, Mashiko A, Katakura Y, et al. Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study. Endocr J. 2021;68(12):1455–1461. doi:10.1507/endocrj.EJ21-0161
   PubMed Web of Science ®Google Scholar
• Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480–1483. doi:10.2337/dc13-2338
   PubMed Web of Science ®Google Scholar
• Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1. Diabetes Obes Metab. 2015;17(10):928–935. doi:10.1111/dom.12494
   PubMed Web of Science ®Google Scholar
• Shimada A, Hanafusa T, Yasui A, et al. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. Diabetes Obes Metab. 2018;20(9):2190–2199. doi:10.1111/dom.13351
   PubMed Web of Science ®Google Scholar
• Haidar A, Yale JF, Lovblom LE, et al. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: a randomized, controlled, non-inferiority, crossover pilot trial. Diabetes Obes Metab. 2021;23(6):1272–1281. doi:10.1111/dom.14335
   PubMed Web of Science ®Google Scholar
• Johnston CK, Eudy-Byrne RJ, Elmokaden A, et al. A Model-Informed Drug Development (MIDD) approach for a low dose of empagliflozin in patients with type 1 diabetes. Pharmaceutics. 2021;13(4):485. doi:10.3390/pharmaceutics13040485
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Roz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X
   PubMed Web of Science ®Google Scholar
• Holt RIG, DeVnes JH. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609–2652. doi:10.1007/s00125-021-05568-3
   PubMed Web of Science ®Google Scholar
• Musso G, Sircana A, Saba F, et al. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression. PLoS Med. 2020;17(12):e1003461. doi:10.1371/journal.pmed.1003461
   PubMed Web of Science ®Google Scholar
• Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860–1870. doi:10.1007/s00125-016-4008-2
   PubMed Web of Science ®Google Scholar
• Groop PH, Phillip M DP, Phillip M, et al. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(10):845–854. doi:10.1016/S2213-8587(20)30280-1
   PubMed Web of Science ®Google Scholar
• Laursen JC, Søndergaard-Heinrich N, de Melo JML, et al. Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. EClinicalMedicine. 2021;37:100895. doi:10.1016/j.eclinm.2021.100895
   PubMedGoogle Scholar
• Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res. 2015;12(2):101–110. doi:10.1177/1479164114563304
   PubMed Web of Science ®Google Scholar
• van Raalte DH, Bjornstand P, Persson F, et al. The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes. Diabetes Care. 2019;42(10):1921–1929. doi:10.2337/dc19-0937
   PubMed Web of Science ®Google Scholar
• Stougaard EB, Rossing P, Cherney D, et al. Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. J Diabetes Complications. 2022;36(8):108257. doi:10.1016/j.jdiacomp.2022.108257
   PubMed Web of Science ®Google Scholar
• Lunder M, Janić M, Japelj M, et al. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):153. doi:10.1186/s12933-018-0797-6
   PubMed Web of Science ®Google Scholar
• Liu H, Shidhar VS, Montemayor D, et al. Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. Diabetes Obes Metab. 2021;23(11):2466–2475. doi:10.1111/dom.14489
   PubMed Web of Science ®Google Scholar
• van Meiel L, Skidhar VS, Montemayor D. Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes. Diabetes Obes Metab. 2021;2021:3.
   Google Scholar
• Seufert J, Lanzinger S, Danne T, et al. Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: improved HbA1c without diabetic ketoacidosis. Diabetes Obes Metab. 2022;24(4):742–746. doi:10.1111/dom.14620
   PubMed Web of Science ®Google Scholar
• Shafer B, Gregory J, Giovanetti E, et al. SGLT2 inhibition increases fasting glucagon but does not restore the counterregulatory hormone response to hypoglycemia in participants with type 1 diabetes. Diabetes. 2022;2022:4.
   Google Scholar
• Baba Y, Ishibashi R, Takasaki A, et al. Effects of sodium glucose co-transporter 2 inhibitors in type 1 diabetes mellitus on body composition and glucose variabilities: single-arm, exploratory trial. Diabetes Ther. 2021;12(5):1415–1427. doi:10.1007/s13300-021-01047-5
   PubMed Web of Science ®Google Scholar
• Teo YN, Ting AZH, Teo YH, et al. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients with diabetes: a network meta-analysis of 111 randomized controlled trials. Am J Cardiovasc Drugs. 2022;22(3):299–323. doi:10.1007/s40256-022-00528-7
   PubMed Web of Science ®Google Scholar
• Palanca A, van Nes F, Pardo F, et al. Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: a European two-center experience. Diabetes Care. 2022;45(3):650–658. doi:10.2337/dc21-1584
   PubMed Web of Science ®Google Scholar
• Fallatah W, Brema I, Abbedallah A, et al. Efficacy and Safety of SGLT2 inhibitors as adjunctive treatment in type 1 diabetes in a tertiary care center in Saudi Arabia. Avicenna J Med. 2022;12(1):10–15. doi:10.1055/s-0041-1742196
   PubMedGoogle Scholar
• Edwards K, Li X, Lingvay I. Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study. J Clin Endocrinol Metab. 2023;108(4):920–930. doi:10.1210/clinem/dgac618
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI, et al. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849–2852. doi:10.1210/jc.2015-1884
   PubMed Web of Science ®Google Scholar
• PDF of HIGHLIGHTS OF PRESCRIBING INFORMATION Farxiga. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s020lbl.pdf. Accessed October 25, 2023.
   Google Scholar
• Available from: https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf. Accessed October 25, 2023.
   Google Scholar
• Zou H, Liu L, Guo J, et al. Sodium–glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: a meta-analysis of randomized controlled trials. J Diabetes Investig. 2021;12:546–556.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702–1710. doi:10.2337/dc16-0691
   PubMed Web of Science ®Google Scholar
• Ahrén B, Hirsh IB, Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39(10):1693–1701. doi:10.2337/dc16-0690
   PubMed Web of Science ®Google Scholar
• Clinicaltrial.gov. Available from: https://clinicaltrials.gov/search?cond=Type%201%20Diabetes%20Mellitus&term=SGLT2-Inhibitors. Accessed 07 November 2023.
   Google Scholar